



Jens-Uwe Blohmer

Kontakt

Jens-Uwe Blohmer

Publikationen (59)

Denkert C, Schneeweiss A, Rey J, Karn T, Hattesoehl A, Weber K, Rachakonda S, Braun M, Huober J, Jank P, Sinn H, Zahm D, Felder B, Hanusch C, Tepy-Szymanski J, Marme F, Fehm T, Thomalla J, Sinn B, Stiewe T, Marczyk M, Blohmer J, van Mackelenbergh M, Schem C, Staib P, Link T, Müller V, Stickeler E, Stover D, Solbach C, Metzger-Filho O, Jackisch C, Geyer C, Fasching P, Pusztai L, Nekljudova V, Untch M, Loibl S. Molecular adaptation to neoadjuvant immunotherapy in triple-negative breast cancer. *Cell Rep Med* 2024; 5:101825.

Möbus V, Lück H, Ladda E, Klare P, Engels K, Schmidt M, Schneeweiss A, Grischke E, Wachsmann G, Forstbauer H, Untch M, Marme F, Blohmer J, Jackisch C, Huober J, Stickeler E, Reinisch M, Link T, Sinn B, Janni W, Denkert C, Seiler S, Solbach C, Schmatloch S, Rey J, Loibl S. GAIN2 trial overall survival with intense versus tailored dose dense chemotherapy in early breast cancer. *NPJ Breast Cancer* 2024; 10:66.

Park-Simon T, Müller V, Albert U, Banys-Paluchowski M, Bauerfeind I, Blohmer J, Budach W, Dall P, Ditsch N, Fallenberg E, Fasching P, Fehm T, Friedrich M, Gerber B, Gluz O, Harbeck N, Hartkopf A, Heil J, Huober J, Jackisch C, Kolberg-Liedtke C, Kreipe H, Krug D, Kühn T, Kümmel S, Loibl S, Luftner D, Lux M, Maass N, Mundhenke C, Reimer T, Rhiem K, Rody A, Schmidt M, Schneeweiss A, Schütz F, Sinn H, Solbach C, Solomayer E, Stickeler E, Thomssen C, Untch M, Wuerstlein R, Wöckel A, Janni W, Thill M. Arbeitsgemeinschaft Gynäkologische Onkologie Recommendations for the Diagnosis and Treatment of Patients with Early Breast Cancer: Update 2024. *Breast Care (Basel)* 2024; 19:165-182.

Thill M, Janni W, Albert U, Banys-Paluchowski M, Bauerfeind I, Blohmer J, Budach W, Dall P, Ditsch N, Fallenberg E, Fasching P, Fehm T, Friedrich M, Gerber B, Gluz O, Harbeck N, Hartkopf A, Heil J, Huober J, Jackisch C, Kolberg-Liedtke C, Kreipe H, Krug D, Kühn T, Kümmel S, Loibl S, Luftner D, Lux M, Maass N, Mundhenke C, Reimer T, Rhiem K, Rody A, Schmidt M, Schneeweiss A, Schütz F, Sinn H, Solbach C, Solomayer E, Stickeler E, Thomssen C, Untch M, Witzel I, Wöckel A, Wuerstlein R, Müller V, Park-Simon T. Arbeitsgemeinschaft Gynäkologische Onkologie Recommendations for the Diagnosis and Treatment of Patients with Locally Advanced and Metastatic Breast Cancer: Update 2024. *Breast Care (Basel)* 2024; 19:183-191.

Massa C, Karn T, Weber K, Schneeweiss A, Hanusch C, Blohmer J, Zahm D, Jackisch C, van Mackelenbergh M, Thomalla J, Marme F, Huober J, Müller V, Schem C, Mueller A, Stickeler E, Biehl K, Fasching P, Untch M, Loibl S, Denkert C, Seliger B. Baseline CD4 and expansion of $\gamma\delta$ T cells correlate with response to durvalumab in triple-negative breast cancer patients. *Clin Transl Med* 2024; 14:e1617.

Fehm T, Müller V, Banys-Paluchowski M, Fasching P, Friedl T, Hartkopf A, Huober J, Loehberg C, Rack B, Riethdorf S, Schneeweiss A, Wallwiener D, Meier-Stiegen F, Krawczyk N, Jaeger B, Reinhardt F, Hoffmann O, Müller L, Wimberger P, Ruckhäberle E, Blohmer J, Cieslik J, Franken A, Niederacher D, Neubauer H, Pantel K, Janni W, DETECT study group. Efficacy of Lapatinib in Patients with HER2-Negative Metastatic Breast Cancer and HER2-Positive Circulating Tumor Cells-The DETECT III Clinical Trial. *Clin Chem* 2024; 70:307-318.

Pfob A, Cai L, Schneeweiss A, Rauch G, Thomas B, Schaeffgen B, Kümmel S, Reimer T, Hahn M, Thill M, Blohmer J, Hackmann J, Malter W, Bekes I, Friedrichs K, Wojcinski S, Joos S, Paepke S, Degenhardt T, Rom J, Rody A, van Mackelenbergh M, Banys-Paluchowski M, Große R, Reinisch M, Karsten M, Sidey-Gibbons C, Wallwiener M, Golatta M, Heil J. ASO Visual Abstract: Minimally-Invasive Breast Biopsy After Neoadjuvant Systemic Treatment to Identify Breast Cancer Patients with Residual Disease for Extended Neoadjuvant Treatment-A New Concept. *Ann Surg Oncol* 2023

Pfob A, Cai L, Schneeweiss A, Rauch G, Thomas B, Schaeffgen B, Kümmel S, Reimer T, Hahn M, Thill M, Blohmer J, Hackmann J, Malter W, Bekes I, Friedrichs K, Wojcinski S, Joos S, Paepke S, Degenhardt T, Rom J, Rody A, van Mackelenbergh M, Banys-Paluchowski M, Große R, Reinisch M, Karsten M, Sidey-Gibbons C, Wallwiener M, Golatta M, Heil J. Minimally Invasive Breast Biopsy After Neoadjuvant Systemic Treatment to Identify Breast Cancer Patients with Residual Disease for Extended Neoadjuvant Treatment: A New Concept. *Ann Surg Oncol* 2023

Link T, Blohmer J, Schmitt W, Kuhlmann J, Just M, Untch M, Stötzer O, Fasching P, Thill M, Reinisch M, Schneeweiss A, Wimberger P, Seiler S, Huober J, Jackisch C, Rhiem K, Hanusch C, Sinn B, Nekljudova V, Loibl S, Denkert C. RANK expression as an independent predictor for response to neoadjuvant chemotherapy in luminal-like breast cancer – a translational insight from the GeparX trial. Clin Cancer Res 2023

Thill M, Kolberg-Liedtke C, Albert U, Banys-Paluchowski M, Bauerfeind I, Blohmer J, Budach W, Dall P, Ditsch N, Fallenberg E, Fasching P, Fehm T, Friedrich M, Gerber B, Gluz O, Harbeck N, Hartkopf A, Heil J, Huober J, Jackisch C, Kreipe H, Krug D, Kühn T, Kümmel S, Loibl S, Luftner D, Lux M, Maass N, Mundhenke C, Reimer T, Rhiem K, Rody A, Schmidt M, Schneeweiss A, Schütz F, Sinn H, Solbach C, Solomayer E, Stickeler E, Thomssen C, Untch M, Witzel I, Wöckel A, Müller V, Wuerstlein R, Janni W, Park-Simon T. AGO Recommendations for the Diagnosis and Treatment of Patients with Locally Advanced and Metastatic Breast Cancer: Update 2023. Breast Care (Basel) 2023; 18:306–315.

Park-Simon T, Müller V, Jackisch C, Albert U, Banys-Paluchowski M, Bauerfeind I, Blohmer J, Budach W, Dall P, Ditsch N, Fallenberg E, Fasching P, Fehm T, Friedrich M, Gerber B, Gluz O, Harbeck N, Hartkopf A, Heil J, Huober J, Kolberg-Liedtke C, Kreipe H, Krug D, Kühn T, Kümmel S, Loibl S, Luftner D, Lux M, Maass N, Mundhenke C, Reimer T, Rhiem K, Rody A, Schmidt M, Schneeweiss A, Schütz F, Sinn H, Solbach C, Solomayer E, Stickeler E, Thomssen C, Untch M, Witzel I, Wöckel A, Wuerstlein R, Janni W, Thill M. Arbeitsgemeinschaft Gynäkologische Onkologie Recommendations for the Diagnosis and Treatment of Patients with Early Breast Cancer: Update 2023. Breast Care (Basel) 2023; 18:289–305.

Huober J, van Mackelenbergh M, Schneeweiss A, Seither F, Blohmer J, Denkert C, Tesch H, Hanusch C, Salat C, Rhiem K, Solbach C, Fasching P, Jackisch C, Reinisch M, Lederer B, Mehta K, Link T, Nekljudova V, Loibl S, Untch M. Identifying breast cancer patients at risk of relapse despite pathological complete response after neoadjuvant therapy. NPJ Breast Cancer 2023; 9:23.

Banys-Paluchowski M, Thill M, Kühn T, Ditsch N, Heil J, Wöckel A, Fallenberg E, Friedrich M, Kümmel S, Müller V, Janni W, Albert U, Bauerfeind I, Blohmer J, Budach W, Dall P, Fasching P, Fehm T, Gluz O, Harbeck N, Huober J, Jackisch C, Kolberg-Liedtke C, Kreipe H, Krug D, Loibl S, Luftner D, Lux M, Maass N, Mundhenke C, Nitz U, Park-Simon T, Reimer T, Rhiem K, Rody A, Schmidt M, Schneeweiss A, Schütz F, Sinn P, Solbach C, Solomayer E, Stickeler E, Thomssen C, Untch M, Witzel I, Gerber B. AGO Recommendations for the Surgical Therapy of Breast Cancer: Update 2022. Geburtshilfe Frauenheilkd 2022; 82:1031–1043.

Ditsch N, Wöckel A, Untch M, Jackisch C, Albert U, Banys-Paluchowski M, Bauerfeind I, Blohmer J, Budach W, Dall P, Fallenberg E, Fasching P, Fehm T, Friedrich M, Gerber B, Gluz O, Harbeck N, Heil J, Huober J, Kreipe H, Krug D, Kühn T, Kümmel S, Kolberg-Liedtke C, Loibl S, Luftner D, Lux M, Maass N, Mundhenke C, Nitz U, Park-Simon T, Reimer T, Rhiem K, Rody A, Schmidt M, Schneeweiss A, Schütz F, Sinn H, Solbach C, Solomayer E, Stickeler E, Thomssen C, Witzel I, Müller V, Janni W, Thill M. AGO Recommendations for the Diagnosis and Treatment of Patients with Early Breast Cancer: Update 2022. Breast Care (Basel) 2022; 17:403–420.

Thill M, Luftner D, Kolberg-Liedtke C, Albert U, Banys-Paluchowski M, Bauerfeind I, Blohmer J, Budach W, Dall P, Fallenberg E, Fasching P, Fehm T, Friedrich M, Gerber B, Gluz O, Harbeck N, Heil J, Huober J, Jackisch C, Kreipe H, Krug D, Kühn T, Kümmel S, Loibl S, Lux M, Maass N, Mundhenke C, Nitz U, Park-Simon T, Reimer T, Rhiem K, Rody A, Schmidt M, Schneeweiss A, Schütz F, Sinn H, Solbach C, Solomayer E, Stickeler E, Thomssen C, Untch M, Witzel I, Wöckel A, Müller V, Janni W, Ditsch N. AGO Recommendations for the Diagnosis and Treatment of Patients with Locally Advanced and Metastatic Breast Cancer: Update 2022. Breast Care (Basel) 2022; 17:421–429.

Huebner H, Tesch H, Brucker S, Blohmer J, Fehm T, Heinrich G, Rezai M, Beckmann M, Fasching P, Janni W, Schneeweiss A, Nabieva N, Jückerstock J, Häberle L, Müller V, Schrader I, Lorenz R, Forstbauer H, Fink V, Schochter F, Bekes I, Mahner S, Rack B. MUC1 (CA27.29) before and after Chemotherapy and Prognosis in High-Risk Early Breast Cancer Patients. Cancers (Basel) 2022; 14

Pfob A, Joos S, Paepke S, Degenhardt T, Rom J, Rody A, van Mackelenbergh M, Banys-Paluchowski M, Große R, Reinisch M, Karsten M, Golatta M, Wojcinski S, Friedrichs K, Bekes I, Sidey-Gibbons C, Rauch G, Thomas B, Schaefgen B, Kuemmel S, Reimer T, Hahn M, Thill M, Blohmer J, Hackmann J, Malter W, Heil J. Intelligent Vacuum-Assisted Biopsy to Identify Breast Cancer Patients With Pathologic Complete Response (ypT0 and ypN0) After Neoadjuvant Systemic Treatment for Omission of Breast and Axillary Surgery. J Clin Oncol 2022;JCO2102439.

Gerber B, Untch M, Kast K, Jackisch C, Thomalla J, Seither F, Blohmer J, Rhiem K, Fasching P, Nekljudova V, Loibl S, Hahn M, Klare P, Ataseven B, Schneeweiss A, Möbus V, Golatta M, Tesch H, Krug D, Hanusch C, Denkert C, Lübke K, Heil J, Huober J, Kühn T. Pathological Response in the Breast and Axillary Lymph Nodes after Neoadjuvant Systemic Treatment in Patients with Initially Node-Positive Breast Cancer Correlates with Disease Free Survival: An Exploratory Analysis of the GeparOcto Trial. *Cancers (Basel)* 2022; 14

Blohmer J, Jackisch C, Rhiem K, Solbach C, Hanusch C, Seither F, Denkert C, Engels K, Nekljudova V, Loibl S, Thill M, Huober J, Link T, Reinisch M, Just M, Untch M, Stötzer O, Fasching P, Schneeweiss A, Wimberger P, Seiler S, GBG and AGO-B. Effect of Denosumab Added to 2 Different nab-Paclitaxel Regimens as Neoadjuvant Therapy in Patients With Primary Breast Cancer: The GeparX 2 × 2 Randomized Clinical Trial. *JAMA Oncol* 2022; 8:1010-1018.

Schneeweiss A, Blohmer J, Fasching P, Solbach C, Schmutzler R, Huober J, Rhiem K, Nekljudova V, Lübke K, Loibl S, Jackisch C, Untch M, Link T, Michel L, Möbus V, Tesch H, Klare P, Hahnen E, Denkert C, Kast K, Pohl-Rescigno E, Hanusch C, GBG and AGO-B. Survival analysis of the randomised phase III GeparOcto trial comparing neoadjuvant chemotherapy of intense dose-dense epirubicin, paclitaxel, cyclophosphamide versus weekly paclitaxel, liposomal doxorubicin (plus carboplatin in triple-negative breast cancer) for patients with high-risk early breast cancer. *Eur J Cancer* 2021

Möbus V, Reinisch M, Link T, Sinn B, Janni W, Denkert C, Furlanetto J, Engels K, Solbach C, Schmatloch S, Rey J, Burchardi N, Loibl S, Stickeler E, Huober J, Lück H, Ladda E, Klare P, Schmidt M, Schneeweiss A, Grischke E, Wachsmann G, Forstbauer H, Untch M, Marme F, Blohmer J, Jackisch C, GBG and AGO-B. Phase III randomised trial comparing intense dose-dense chemotherapy to tailored dose-dense chemotherapy in high-risk early breast cancer (GAIN-2). *Eur J Cancer* 2021; 156:138-148.

Denkert C, Huober J, Rhiem K, Marme F, Reimer T, Schmidt M, Sinn B, Janni W, Stickeler E, Michel L, Stötzer O, Hahnen E, Furlanetto J, Seiler S, Nekljudova V, Untch M, Solbach C, Lübke K, Seither F, Schneeweiss A, Link T, Blohmer J, Just M, Wimberger P, Forberger A, Tesch H, Jackisch C, Schmatloch S, Reinisch M, Solomayer E, Schmitt W, Hanusch C, Fasching P, Loibl S. Clinical and molecular characteristics of HER2-low-positive breast cancer: pooled analysis of individual patient data from four prospective, neoadjuvant clinical trials. *Lancet Oncol* 2021; 22:1151-1161.

Marme F, Loibl S, Lederer B, Tesch H, Hanusch C, Denkert C, Rey J, Rhiem K, Link T, Nekljudova V, Jackisch C, Fasching P, Huober J, Blohmer J, Schneeweiss A, Michel L, Solbach C, Untch M. Utility of the CPS + EG scoring system in triple-negative breast cancer treated with neoadjuvant chemotherapy. *Eur J Cancer* 2021; 153:203-212.

Thill M, Schmidt M, Rody A, Rhiem K, Reimer T, Park-Simon T, Nitz U, Mundhenke C, Maass N, Lux M, Schneeweiss A, Schütz F, Sinn H, Janni W, Müller V, Wöckel A, Witzel I, Untch M, Thomssen C, Stickeler E, Solomayer E, Solbach C, Luftner D, Loibl S, Dall P, Budach W, Blohmer J, Bauerfeind I, Banys-Paluchowski M, Albert U, Jackisch C, Friedrich M, Kolberg-Liedtke C, Fallenberg E, Fasching P, Fehm T, Kümmel S, Kühn T, Krug D, Kreipe H, Huober J, Heil J, Harbeck N, Gluz O, Gerber B, Ditsch N. AGO Recommendations for the Diagnosis and Treatment of Patients with Early Breast Cancer: Update 2021. *Breast Care (Basel)* 2021; 16:214-227.

Ditsch N, Schmidt M, Rody A, Rhiem K, Reimer T, Park-Simon T, Nitz U, Mundhenke C, Maass N, Lux M, Schneeweiss A, Schütz F, Sinn H, Janni W, Müller V, Wöckel A, Witzel I, Untch M, Thomssen C, Stickeler E, Solomayer E, Solbach C, Luftner D, Loibl S, Fallenberg E, Dall P, Budach W, Blohmer J, Bauerfeind I, Banys-Paluchowski M, Albert U, Kolberg-Liedtke C, Friedrich M, Fasching P, Fehm T, Gerber B, Kümmel S, Kühn T, Krug D, Kreipe H, Jackisch C, Huober J, Heil J, Harbeck N, Gluz O, Thill M. AGO Recommendations for the Diagnosis and Treatment of Patients with Locally Advanced and Metastatic Breast Cancer: Update 2021. *Breast Care (Basel)* 2021; 16:228-235.

Furlanetto J, Lederer B, Gerber B, Zahm D, Bauerfeind I, Nekljudova V, Hanusch C, Jackisch C, Link T, Hahnen E, Loibl S, Couch F, Schmutzler R, Möbus V, Schneeweiss A, Rhiem K, Tesch H, Blohmer J, Lübke K, Untch M, Salat C, Huober J, Klare P, Fasching P. Germline BRCA1/2 mutations and severe haematological toxicities in patients with breast cancer treated with neoadjuvant chemotherapy. *Eur J Cancer* 2021; 145:44-52.

De Gregorio A, Schneeweiss A, Tesch H, Mahner S, Brucker S, Blohmer J, Fehm T, Heinrich G, Lato K, Beckmann M, Rack B, Andergassen U, Bekes I, Fink V, Häberle L, Fasching P, Müller V, Schrader I, Lorenz R, Forstbauer H, Friedl T, Bauer E, De Gregorio N, Deniz M, Janni W. Gemcitabine as adjuvant chemotherapy in patients with high-risk early breast cancer—results from the randomized phase III SUCCESS-A trial. *Breast Cancer Res* 2020; 22:111.

Heil J, Friedrichs K, Wojcinski S, Joos S, Paepke S, Ditsch N, Rody A, Große R, van Mackelenbergh M, Reinisch M, Karsten M, Golatta M, Bekes I, Malter W, Hackmann J, Pfob A, Sinn H, Rauch G, Bach P, Thomas B, Schaeffgen B, Kuemmel S, Reimer T, Hahn M, Thill M, Blohmer J, RESPONDER Investigators. Diagnosing Pathologic Complete Response in the Breast After Neoadjuvant Systemic Treatment of Breast Cancer Patients by Minimal Invasive Biopsy: Oral Presentation at the San Antonio Breast Cancer Symposium on Friday, December 13, 2019, Program Number GS5-03. *Ann Surg* 2020

Thill M, Mundhenke C, Moebus V, Maass N, Lux M, Luftner D, Loibl S, Kümmel S, Kühn T, Kreipe H, Park-Simon T, Reimer T, Rhiem K, Wöckel A, Witzel I, Thomssen C, Stickeler E, Solomayer E, Solbach C, Schneeweiss A, Schmidt M, Rody A, Huober J, Heil J, Banys-Paluchowski M, Albert U, Müller V, Janni W, Friedrich M, Krug D, Jackisch C, Kolberg-Liedtke C, Untch M, Bauerfeind I, Blohmer J, Budach W, Harbeck N, Hanf V, Gluz O, Gerber B, Fehm T, Fasching P, Fallenberg E, Diel I, Dall P, Ditsch N. AGO Recommendations for the Diagnosis and Treatment of Patients with Locally Advanced and Metastatic Breast Cancer: Update 2020. *Breast Care (Basel)* 2020; 15:294-309.

Werutsky G, Nekljudova V, Vladimirova V, Kühn T, Rhiem K, Huober J, Krug D, Link T, Schneeweiss A, Gerber B, Jackisch C, Tesch H, Denkert C, Seiler S, Blohmer J, Fasching P, Hanusch C, Untch M, Loibl S. Locoregional recurrence risk after neoadjuvant chemotherapy: A pooled analysis of nine prospective neoadjuvant breast cancer trials. *Eur J Cancer* 2020; 130:92-101.

Massa C, Müller V, Schem C, Mueller A, Stickeler E, Biehl K, Fasching P, Untch M, Loibl S, Weber K, Huober J, Marme F, Karn T, Denkert C, Schneeweiss A, Hanusch C, Blohmer J, Zahm D, Jackisch C, van Mackelenbergh M, Thomalla J, Seliger B. Differential effect on different immune subsets of neoadjuvant chemotherapy in patients with TNBC. *J Immunother Cancer* 2020; 8

Sinn B, Denkert C, Seliger B, von Minckwitz G, Huober J, Ataseven B, Stickeler E, Schem C, Marme F, Klauschen F, Taube E, Karn T, Blohmer J, Symmans W, Fasching P, Schmitt W, Weber K, Loibl S. Human leucocyte antigen class I in hormone receptor-positive, HER2-negative breast cancer: association with response and survival after neoadjuvant chemotherapy. *Breast Cancer Res* 2019; 21:142.

Krug D, Huober J, Jackisch C, Kümmel S, Paepke S, Schem C, Schneeweiss A, Untch M, Debus J, von Minckwitz G, Kühn T, Hilfrich J, Heil J, Lederer B, Seither F, Nekljudova V, Ataseven B, Blohmer J, Costa S, Denkert C, Ditsch N, Gerber B, Hanusch C, Loibl S. Post-Mastectomy Radiotherapy After Neoadjuvant Chemotherapy in Breast Cancer: A Pooled Retrospective Analysis of Three Prospective Randomized Trials. *Ann Surg Oncol* 2019; 26:3892-3901.

Untch M, Hackmann J, Blohmer J, Rhiem K, Schmitt W, Furlanetto J, Gerber B, Huober J, Nekljudova V, von Minckwitz G, Hanusch C, Just M, Fasching P, Jackisch C, Schneeweiss A, Schmatloch S, Aktas B, Denkert C, Schem C, Wiebringhaus H, Kümmel S, Warm M, Loibl S. NAB-Paclitaxel Improves Disease-Free Survival in Early Breast Cancer: GBG 69-GeparSepto. *J Clin Oncol* 2019; 37:2226-2234.

Laakmann E, Ingold-Heppner B, Huober J, Hanusch C, Jackisch C, Reinisch M, Untch M, von Minckwitz G, Nekljudova V, Müller V, Blohmer J, Zahm D, Witzel I, Fasching P, Rezai M, Schem C, Solbach C, Tesch H, Klare P, Schneeweiss A, Salat C, Loibl S. Development of central nervous system metastases as a first site of metastatic disease in breast cancer patients treated in the neoadjuvant trials GeparQuinto and GeparSixto. *Breast Cancer Res* 2019; 21:60.

Denkert C, Müller V, Klauschen F, Ataseven B, Engels K, Kammler R, Pfitzner B, Dietel M, Fasching P, Colleoni M, Blohmer J, Mehta K, Budczies J, Regan M, Loibl S, Dell'Orto P, von Minckwitz G, Mastropasqua M, Solbach C, Thürlimann B, Viale G. Clinical and analytical validation of Ki-67 in 9069 patients from IBCSG VIII + IX, BIG1-98 and GeparTrio trial: systematic modulation of interobserver variance in a comprehensive in silico ring trial. *Breast Cancer Res Treat* 2019; 176:557-568.

Schneeweiss A, Ingold-Heppner B, Blohmer J, Rezai M, Frank M, Engels K, Rhiem K, Fasching P, Nekljudova V, von Minckwitz G, Thomalla J, Jackisch C, Kast K, Möbus V, Tesch H, Hanusch C, Denkert C, Lübke K, Huober J, Klare P, Kümmel S, Untch M, Loibl S. Intense dose-dense epirubicin, paclitaxel, cyclophosphamide versus weekly paclitaxel, liposomal doxorubicin (plus carboplatin in triple-negative breast cancer) for neoadjuvant treatment of high-risk early breast cancer (GeparOcto-GBG 84): A randomised phase III trial. *Eur J Cancer* 2018; 106:181-192.

Gnant M, Montagna G, Meani F, Mechera R, Landin J, Knauer M, Kappos E, Hauser N, Harder Y, Günthert A, Ganz-Blättler U, Fulco I, Fehr M, Ritter M, Saccilotto R, Schwab F, Sacchini V, Pusic A, El-Tamer M, Romics L, Wyld L, Tansley A, Kovacs T, Lohsiriwat V, Soysal S, Zeindler J, Tausch C, Steffens D, Farhadi J, Dubsy P, Heil J, Blohmer J, Paulinelli R, Urban C, Brenelli F, Biazus J, Fitzal F, Reitsamer R, Koller R, Bjelic-Radisic V, Kurzeder C, Haug M, Hoffmann J, Matrai Z, Catanuto G, Bucher S, Svensjö T, de Boniface J, Rubio I, Gouveia P, Cardoso M, Olsha O, Allweis T, Hadar T, Barry M, Gentilini O, Galimberti V, Weber W. Oncoplastic Breast Consortium consensus conference on nipple-sparing mastectomy. *Breast Cancer Res Treat* 2018

Fasching P, Huober J, Liedtke C, Weinshilboum R, Wang L, Ingle J, Müller V, Nekljudova V, Weber K, Rack B, Rübner M, von Minckwitz G, Fehm T, Blohmer J, Costa S, Loibl S, Hu C, Hart S, Shimelis H, Moore R, Schem C, Tesch H, Untch M, Hilfrich J, Rezai M, Gerber B, Couch F. BRCA1/2 Mutations and Bevacizumab in the Neoadjuvant Treatment of Breast Cancer: Response and Prognosis Results in Patients With Triple-Negative Breast Cancer From the GeparQuinto Study. *J Clin Oncol* 2018; 36:2281-2287.

Untch M, Loibl S, Nekljudova V, Fehm T, Hauschild M, Blohmer J, Kunz G, Jackisch C, Solbach C, Huober J, Hanusch C, Eggemann H, Tesch H, Fasching P, Rezai M, Schem C, Gerber B, von Minckwitz G, GBG and the AGO-B Study Group. Survival Analysis After Neoadjuvant Chemotherapy With Trastuzumab or Lapatinib in Patients With Human Epidermal Growth Factor Receptor 2-Positive Breast Cancer in the GeparQuinto (G5) Study (GBG 44). *J Clin Oncol* 2018; 36:1308-1316.

Denkert C, Engels K, Schneeweiss A, Hartmann A, Noske A, Fasching P, Jackisch C, van Mackelenbergh M, Sinn P, Schem C, Hanusch C, Untch M, Kümmel S, Pfitzner B, Karn T, von Minckwitz G, Darb-Esfahani S, Lederer B, Heppner B, Weber K, Budczies J, Huober J, Klauschen F, Furlanetto J, Schmitt W, Blohmer J, Loibl S. Tumour-infiltrating lymphocytes and prognosis in different subtypes of breast cancer: a pooled analysis of 3771 patients treated with neoadjuvant therapy. *Lancet Oncol* 2017; 19:40-50.

van Mackelenbergh M, Weber K, von Minckwitz G, Untch M, Schneeweiss A, Müller V, Kümmel S, Blohmer J, Fasching P, Huober J, Hanusch C, Jackisch C, Stickeler E, Marme F, Schem C, Karn T, Nekljudova V, Denkert C, Loibl S. Outcome after neoadjuvant chemotherapy in estrogen receptor-positive and progesterone receptor-negative breast cancer patients: a pooled analysis of individual patient data from ten prospectively randomized controlled neoadjuvant trials. *Breast Cancer Res Treat* 2017; 167:59-71.

Weber W, Reitsamer R, Koller R, Heil J, Hahn M, Blohmer J, Hoffmann J, Solbach C, Heitmann C, Gerber B, Haug M, Bjelic-Radisic V, Dubsy P, Fitzal F, Soysal S, El-Tamer M, Sacchini V, Knauer M, Tausch C, Hauser N, Günthert A, Harder Y, Kappos E, Schwab F, Kurzeder C. First international consensus conference on standardization of oncoplastic breast conserving surgery. *Breast Cancer Res Treat* 2017; 165:139-149.

Reinisch M, Nekljudova V, Untch M, Lederer B, Rhiem K, Schneeweiss A, Kümmel S, Jackisch C, Hanusch C, Denkert C, Blohmer J, von Minckwitz G, Huober J, Loibl S. pCR rates in patients with bilateral breast cancer after neoadjuvant anthracycline-taxane based-chemotherapy - A retrospective pooled analysis of individual patients data of four German neoadjuvant trials. *Breast* 2017; 32:73-78.

Marme F, von Minckwitz G, Untch M, Paepke S, Loibl S, Kümmel S, Jackisch C, Huober J, Hilfrich J, Hanusch C, Gerber B, Eidtmann H, Denkert C, Costa S, Blohmer J, Lederer B, Schneeweiss A. Utility of the CPS+EG staging system in hormone receptor-positive, human epidermal growth factor receptor 2-negative breast cancer treated with neoadjuvant chemotherapy. *Eur J Cancer* 2015; 53:65-74.

Hein A, Ekici A, Hanusch C, Huober J, Liedtke C, Mau C, Moisse M, Müller V, Nekljudova V, Peuteman G, Rack B, Rübner M, Van Brussel T, Wang L, Weinshilboum R, Loibl S, Beckmann M, Kunz G, Lambrechts D, von Minckwitz G, Häberle L, Eidtmann H, Tesch H, Untch M, Hilfrich J, Schem C, Rezai M, Gerber B, Dan Costa S, Blohmer J, Schwedler K, Kittel K, Fehm T, Fasching P. Genetic variants in VEGF pathway genes in neoadjuvant breast cancer patients receiving bevacizumab: Results from the randomized phase III GeparQuinto study. *Int J Cancer* 2015; 137:2981-8.

Loibl S, Mehta K, Nekljudova V, Blohmer J, Costa S, Denkert C, Eidtmann H, Gerber B, Hanusch C, Hilfrich J, Huober J, Schneeweiss A, Kümmel S, Paepke S, Untch M, Lederer B, Jackisch C, von Minckwitz G. Outcome after neoadjuvant chemotherapy in young breast cancer patients: a pooled analysis of individual patient data from eight prospectively randomized controlled trials. *Breast Cancer Res Treat* 2015; 152:377-87.

Jackisch C, Blohmer J, Costa S, Decker T, Diel I, Fasching P, Fehm T, Janni W, Lück H, Maass N, Scharl A, Beckmann M, Loibl S, Thomssen C, Harbeck N, Huober J, von Minckwitz G, Gerber B, Kreipe H, Liedtke C, Marschner N, Möbus V, Scheithauer H, Schneeweiss A, Untch M. 14th St. Gallen International Breast Cancer Conference 2015: Evidence, Controversies, Consensus - Primary Therapy of Early Breast Cancer: Opinions Expressed by German Experts. *Breast Care (Basel)* 2015; 10:211-9.

Klauschen F, Denkert C, Dietel M, Lederer B, Mehta K, Erbstöber E, Rüdiger T, Huober J, Blohmer J, Gerber B, Loibl S, Schmitt W, Wienert S, von Minckwitz G. Standardized Ki67 Diagnostics Using Automated Scoring--Clinical Validation in the GeparTrio Breast Cancer Study. *Clin Cancer Res* 2014; 21:3651-7.

Gerber B, Loibl S, Nekljudova V, Hauschild M, Huober J, Blohmer J, Kunz G, Jackisch C, Solbach C, Hanusch C, Kittel K, Schrader I, Eggemann H, Tesch H, Fasching P, Rezai M, Eidtmann H, von Minckwitz G, Untch M. Surgical outcome after neoadjuvant chemotherapy and bevacizumab: results from the GeparQuinto study (GBG 44). *Ann Surg Oncol* 2014; 21:2517-24.

Loibl S, Denkert C, Hilfrich J, Konecny G, Fett W, Stickeler E, Harbeck N, Mehta K, Nekljudova V, von Minckwitz G, Huober J, Kümmel S, Volz C, Mau C, Blohmer J, Costa S, Eidtmann H, Fasching P, Gerber B, Hanusch C, Jackisch C, Untch M. Response and prognosis after neoadjuvant chemotherapy in 1,051 patients with infiltrating lobular breast carcinoma. *Breast Cancer Res Treat* 2014; 144:153-62.

Huober J, Kümmel S, Mau C, Jackisch C, Khandan F, Costa S, Krabisch P, Loibl S, Nekljudova V, Untch M, Höß C, Gerber B, Fasching P, Hanusch C, Rezai M, Eidtmann H, Kittel K, Hilfrich J, Schwedler K, Blohmer J, Tesch H, Minckwitz G. Neoadjuvant chemotherapy with paclitaxel and everolimus in breast cancer patients with non-responsive tumours to epirubicin/cyclophosphamide (EC) ± bevacizumab - results of the randomised GeparQuinto study (GBG 44). *Eur J Cancer* 2013; 49:2284-93.

von Minckwitz G, Mehta K, Nekljudova V, Denkert C, Konecny G, Kaufmann M, Jackisch C, Huober J, Hilfrich J, Eiermann W, Gerber B, Fasching P, Eidtmann H, Costa S, Blohmer J, Untch M, Loibl S. Definition and impact of pathologic complete response on prognosis after neoadjuvant chemotherapy in various intrinsic breast cancer subtypes. *J Clin Oncol* 2012; 30:1796-804.

von Minckwitz G, Blohmer J, Huober J, Hauschild M, Fehm T, Müller B, Denkert C, Loibl S, Nekljudova V, Untch M, German Breast Group, Kunz G, Jackisch C, Gerber B, Eidtmann H, Rezai M, Fasching P, Tesch H, Eggemann H, Schrader I, Kittel K, Hanusch C, Kreienberg R, Solbach C, Arbeitsgemeinschaft Gynäkologische Onkologie-Breast Study Groups. Neoadjuvant chemotherapy and bevacizumab for HER2-negative breast cancer. *N Engl J Med* 2012; 366:299-309.

Untch M, Gerber B, Rezai M, Jackisch C, Huober J, Kühn T, Nekljudova V, von Minckwitz G, German Breast Group (GBG), Hanusch C, Tesch H, Kreienberg R, Loibl S, Bischoff J, Eidtmann H, Kaufmann M, Blohmer J, Hilfrich J, Strumberg D, Fasching P, Arbeitsgemeinschaft Gynäkologische Onkologie-Breast (AGO-B) Study Group. Lapatinib versus trastuzumab in combination with neoadjuvant anthracycline-taxane-based chemotherapy (GeparQuinto, GBG 44): a randomised phase 3 trial. *Lancet Oncol* 2012; 13:135-44.

von Minckwitz G, Gerber B, du Bois A, Huober J, Hanusch C, Konecny G, Fett W, Stickeler E, Harbeck N, Müller V, Jackisch C, Hilfrich J, Mehta K, Untch M, Nüesch E, Loibl S, Kaufmann M, Kümmel S, Fasching P, Eiermann W, Blohmer J, Costa S, Jüni P. Impact of treatment characteristics on response of different breast cancer phenotypes: pooled analysis of the German neo-adjuvant chemotherapy trials. *Breast Cancer Res Treat* 2010; 125:145-56.

von Minckwitz G, Kühn T, du Bois A, Blohmer J, Thomssen C, Dan Costa S, Jackisch C, Kaufmann M, Mehta K, Hanusch C, Gerber B, Rezai M, Loibl S, Fasching P, Huober J, Tesch H, Bauerfeind I, Hilfrich J, Eidtmann H, Untch M. Capecitabine in addition to anthracycline- and taxane-based neoadjuvant treatment in patients with primary breast cancer: phase III GeparQuattro study. *J Clin Oncol* 2010; 28:2015-23.

Untch M, Kühn T, du Bois A, Blohmer J, Thomssen C, Dan Costa S, Jackisch C, Kaufmann M, Mehta K, Hanusch C, Gerber B, Rezai M, Loibl S, Fasching P, Huober J, Tesch H, Bauerfeind I, Hilfrich J, Eidtmann H, von Minckwitz G. Neoadjuvant treatment with trastuzumab in HER2-positive breast cancer: results from the GeparQuattro study. *J Clin Oncol* 2010; 28:2024-31.

Costa S, Tesch H, Gerber B, Baumann K, Thomssen C, Breitbach G, Ibishi S, Jackisch C, Mehta K, Weiss E, Ataseven B, Loibl S, Kaufmann M, Zahm D, Hilfrich J, Huober J, Eidtmann H, du Bois A, Blohmer J, von Minckwitz G. Neoadjuvant chemotherapy shows similar response in patients with inflammatory or locally advanced breast cancer when compared with operable breast cancer: a secondary analysis of the GeparTrio trial data. *Journal of clinical oncology : official journal of the American Society of Clinical Oncology* 2010; 28:83-91.

Projekte (0)

Keine Resultate gefunden.

Kantonsspital St.Gallen

Rorschacher Strasse 95

CH-9007 St.Gallen

T: +41 71 494 11 11

support.forschung@kssg.ch